✦ LIBER ✦

The safe use of cisplatin in hyperthermic isolated limb perfusion systems

✍ Scribed by James M. Roseman; Daniel Tench; Lester R. Bryant

Publisher: John Wiley and Sons
Year: 1985
Tongue: English
Weight: 355 KB
Volume: 56
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19850815)56:4<742::aid-cncr2820560407>3.0.co;2-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hyperthermic isolated limb perfusion for

Hyperthermic isolated limb perfusion for the treatment of soft tissue sarcomas

✍ Heimen Schraffordt Koops; Alexander M. M. Eggermont; Danielle Liénard; Bin B. R. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 36 KB 👁 2 views

Hyperthermic isolated limb perfusion (HILP) with various chemotherapeutic agents has been used for the local treatment of high-grade soft tissue sarcomas (STS) of the extremities, but in most cases, with a disappointing result. Most such regimens certainly should not be considered superior to surger

Isolation perfusion with cisplatin for m

Isolation perfusion with cisplatin for malignant melanoma of the limbs

✍ Ehud S. Klein; Gur Y. Ben-Ari 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 326 KB 👁 2 views

Hyperthermic isolated regional perfusion

Hyperthermic isolated regional perfusion in the treatment of extremity melanoma in children and adolescents

✍ Peter C. Baas; Harald J. Hoekstra; Heimen Schraffordt Koops; Wolter J. Oosterhui 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 482 KB 👁 1 views

Intractible cutaneous non-Hodgkin's lymp

Intractible cutaneous non-Hodgkin's lymphoma of the lower limb. Complete remission after sequential regional isolated hyperthermic perfusion and perfusion with 1-phenylalanine-mustard (melphalan, L-pam)

✍ Ruud F. M. Jansen; Bert N. van Geel; Jacoba Van de rzee; Anton Hagenbeek; Peter 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 369 KB 👁 1 views

A 61-year-old man with an intractible and progressively disabling cutaneous non-Hodgkin's lymphoma (NHL) in the lower limb was treated with sequential regional isolated perfusion at 10-day intervals. The first perfusion was hyperthermic (40.2-43.1 "C tumor-temperature); the second was at controlled

A Phase I trial of continuous hypertherm

A Phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis

✍ David L. Bartlett; Joseph F. Buell; Steven K. Libutti; Eddie Reed; Kang Bo Lee; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB 👁 1 views

## BACKGROUND. Tumor necrosis factor (TNF), hyperthermia, and cisplatin have synergistic cytotoxicity against cancer cells in vitro. This combination may be well suited to the regional treatment of peritoneal tumor spread in patients. Continuous hyperthermic peritoneal perfusion (CHPP) is a techni

Tumor necrosis factor-alpha in isolated

Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer: The Rotterdam Preclinical-Clinical Program

✍ Eric R. Manusama; Peet T.G. A. Nooijen; Timo L.M. Ten Hagen; Alex H. Van Der Vee 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 46 KB 👁 1 views

The clinical success of the application of tumor necrosis factor-α (TNFα) in isolated limb perfusions in patients with advanced sarcomas, melanomas and other tumors has renewed the interest in this agent as an anticancer drug. At the Rotterdam Cancer Center, we have developed an interactive preclini